Surface Oncology (SURF) has an average rating of buy and price targets ranging from $10 to $14, according to analysts polled by Capital IQ. (MT Newswires...
Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a...
Surface Oncology (SURF) said Thursday that it has received a $30 million milestone payment as GlaxoSmithKline (GSK) has dosed the first patient in a phase...
Surface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...
| Address | 50 Hampshire Street Cambridge, Massachusetts 02139 |
| Phone | +1.617.714.4096 |
| Number of Employees | 76 |
| Recent SEC Filing | 05/09/2022 10-Q |
| President, Chief Executive Officer & Director | Robert W. Ross |
| Chief Financial Officer | Jessica Fees |
| Chief Scientific Officer | Vito J. Palombella |
| Chief Medical Officer | Alison M. O'Neill |
| Price Open | $1.99 |
| Previous Close | $1.97 |
| 52 Week Range | $1.83 - 9.57 |
| Market Capitalization | $104.8 M |
| Shares Outstanding | 54.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.77 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.4 M |
| Net Profit Margin | -2,919.83% |
| Return on Equity | -56.34% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
